THERAPY DOSSIER · th-64324e117b5e

CR2-Crry and CR2-factor H (CR2-fH) targeted complement inhibitor fusion proteins

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22566568 ↗2012Reported benefit

Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis.

MouseChemical/toxinC57BL/6 wild-type, C3-/-, factor B-/- and C1q/MBL double-deficientIntraperitoneal0.25 mg per injectionTherapeutic protocol beginning on day 5, on replacement of DSS with normal drin…

Model: Acute dextran sulfate sodium (DSS) induced colitis, 5% w/v in drinking water ad libitum for 5 days, with or without a 7-day recovery period on normal water

C3-/- and factor B-/- mice were protected at day 5 while C1q/MBL-/- mice had worse disease, but all complement-deficient mice died during the recovery period (C1q/MBL-/- by day 2, C3-/- and fB-/- by day 5) with raised serum endotoxin; antibiotics rescued 100% of them. Therapeutic CR2-Crry and CR2-f…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…